SI200130: Triamterene-d5 label-new Methyl [(2S)-1-{(2S)-2-[4-(4’-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate

Methyl [(2S)-1-{(2S)-2-[4-(4’-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate

β-D-GalNAc(Ac)3-Et-N3

Fmoc-L-Ser((Ac)3-Xyl-β-D)-OH

Mannose-6-phosphonate (M6Pn) ligands are less sensitive to phosphatase degradation than natural Mannose-6-phosphate (M6P) ligands and may offer improved in vivo stability for LYTACs therapeutic applications

SI200130: Triamterene-d5 label-new Methyl [(2S)-1-{(2S)-2-[4-(4’-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamateC12H6D5N7 258. 29 Hypertension, Edema Triamterene d5 Dyrenium d5,Dyazide d5,Maxzide d5, 6 phenylpteridine 2,4,7 triamine d5